Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards is focused on positioning TAVR for long-term growth ... that those who received Edwards’ newest generation SAPIEN 3 Ultra RESILIA valve have experienced outstanding one-year outcomes.

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

California-based Edwards (NYSE:EW) its only sell-equivalent rating on Wall Street amid 14 buy-equivalent ratings. Citing an FDA dataset from the company's Partner 3 trial for its TAVR heart valve ...

The TAVR market has experienced a slowdown, with Edwards reducing its 2024 and second half of the year worldwide TAVR outlook to 5-7% year-over-year, down from the previously anticipated 8-10% growth.

However, there is a large population af7licted with aortic stenosis that do not exhibit symptoms which is monitored rather than treated with TAVR. Edwards presented data from its EARLY TAVR trial ...

The FDA approval requires that Edwards Lifesciences conduct two post approval studies. A National Transcatheter Aortic Valve Replacement registry must be developed within four months of the start ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies, has recently faced challenges in its core ...